Literature DB >> 17899133

[Physiotherapeutic and rehabilitation therapy for ankylosing spondylitis. Status quo and are they still necessary in the age of anti-cytokine therapy?].

U Lange1, B Kürten, U Müller-Ladner, C Uhlemann.   

Abstract

Ankylosing spondylitis (AS) is one of the most common chronic inflammatory rheumatic diseases characterized by erosions and bone proliferation with consecutive morphologic and functional deficits. Physiotherapeutic and rehabilitation measures are often necessary for AS patients for their whole life. In recent years, biologicals have substantially improved the outcome in AS patients, but their positive influence on vertebral and joint functions still requires differential indicative physiotherapeutic strategies and rehabilitation, in most cases in combination with effective analgesic and anti-inflammatory medication. Although physical therapy and rehabilitation have not been investigated in large controlled trials, they are essential for the multimodal therapeutic concept of AS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899133     DOI: 10.1007/s00393-007-0217-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  20 in total

1.  [Alternative therapy. Chances in Bechterew disease?].

Authors:  K H Berquet
Journal:  Versicherungsmedizin       Date:  1991-10-01

2.  Patients using chiropractors in North America: who are they, and why are they in chiropractic care?

Authors:  Ian D Coulter; Eric L Hurwitz; Alan H Adams; Barbara J Genovese; Ron Hays; Paul G Shekelle
Journal:  Spine (Phila Pa 1976)       Date:  2002-02-01       Impact factor: 3.468

3.  Effect of physiotherapy on spinal mobility in ankylosing spondylitis.

Authors:  J V Viitanen; J Suni; H Kautiainen; M Liimatainen; H Takala
Journal:  Scand J Rheumatol       Date:  1992       Impact factor: 3.641

Review 4.  Usage of complementary therapies in rheumatology: a systematic review.

Authors:  E Ernst
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 5.  Why I would want to use complementary and alternative therapy: a patient's perspective.

Authors:  M Kanning
Journal:  Rheum Dis Clin North Am       Date:  1999-11       Impact factor: 2.670

6.  Short-term outcomes of treatment for musculoskeletal disorders in a hospital-based alternative and complementary medicine clinic.

Authors:  M L Bullock; A M Pheley; S K Lenz; P D Culliton
Journal:  J Altern Complement Med       Date:  1999-06       Impact factor: 2.579

7.  Factors related to change in global health after group physical therapy in ankylosing spondylitis.

Authors:  A Hidding; S van der Linden
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

8.  Patterns and perceptions of care for treatment of back and neck pain: results of a national survey.

Authors:  Peter M Wolsko; David M Eisenberg; Roger B Davis; Ronald Kessler; Russell S Phillips
Journal:  Spine (Phila Pa 1976)       Date:  2003-02-01       Impact factor: 3.468

9.  Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis.

Authors:  A van Tubergen; R Landewé; L Heuft-Dorenbosch; A Spoorenberg; D van der Heijde; H van der Tempel; S van der Linden
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

10.  Factors associated with body function and disability in patients with ankylosing spondylitis: a cross-sectional study.

Authors:  Albrecht Falkenbach; Annegret Franke; Sjef van der Linden
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

View more
  3 in total

1.  [Molecular physical medicine].

Authors:  U Lange
Journal:  Z Rheumatol       Date:  2012-07       Impact factor: 1.372

Review 2.  [Evidence-based physiotherapeutic strategies for musculoskeletal pain].

Authors:  U Lange; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2008-12       Impact factor: 1.372

3.  [Patient evaluation of the German version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis].

Authors:  U Kiltz; E Feldtkeller; J Braun
Journal:  Z Rheumatol       Date:  2008-12       Impact factor: 1.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.